HIGHLIGHTS
- who: Rachel Bernard from the Laboratory values have published the article: Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes, in the Journal: (JOURNAL) of June/30,/2020
- what: The authors demonstrate that there is reduced detection of expressed C. difficile toxin from patients with IBD patients when compared to the non-IBD population.
- future: Future studies will be required to assess the role of more sensitive toxin assays in IBD and the potential impact of CDI specific therapies on clinical outcomes.
SUMMARY . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.